UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000044733
Receipt number R000051090
Scientific Title Effect of Single Ingestion of Coffee Chlorogenic Acid on Postprandial Serum Triglyceride Levels: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study
Date of disclosure of the study information 2021/07/05
Last modified on 2022/04/01 18:05:36

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of Single Ingestion of Coffee Chlorogenic Acid on Postprandial Serum Triglyceride Levels: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study

Acronym

Beneficial Effects of Coffee Chlorogenic Acid on Postprandial Serum Triglyceride Levels

Scientific Title

Effect of Single Ingestion of Coffee Chlorogenic Acid on Postprandial Serum Triglyceride Levels: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study

Scientific Title:Acronym

Beneficial Effects of Coffee Chlorogenic Acid on Postprandial Serum Triglyceride Levels

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To prove clinical benefits associated with single ingestion of coffee chlorogenic acid on postprandial serum triglyceride levels in a randomized, double-blind, placebo-controlled, crossover study.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase



Assessment

Primary outcomes

Delta TG, incremental area under the curve (iAUC) of TG (0 to 6 hours)

Key secondary outcomes

TG, area under the curve (AUC) of TG, RLP-C, delta RLP-C, AUC of RLP-C, iAUC of RLP-C, NEFA, delta NEFA, AUC of NEFA, iAUC of NEFA, blood glucose, delta blood glucose, AUC of blood glucose, iAUC of blood glucose, insulin, delta insulin, AUC of insulin, iAUC of insulin (0 to 6 hours)


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration


Blocking

YES

Concealment

No need to know


Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Single ingestion of decaffeinated green coffee bean extract powder with high-fat meal, and take washout period for 1 week, and then, single ingestion of placebo powder with high-fat meal.

Interventions/Control_2

Single ingestion of placebo powder with high-fat meal, and take washout period for 1 week, and then, single ingestion of decaffeinated green coffee bean extract powder with high-fat meal.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1. Subjects who fully understand significance, content and purpose of this study and who agree to participate in this study with a written informed consent.
2. Subjects whose fasting serum triglyceride levels are 100 mg/dl or more and 149 mg/dl or less.
3. Subjects with relatively high postprandial serum triglyceride levels.

Key exclusion criteria

1. Subjects who are under physician's advice, treatment, and/or medication for dyslipidemia and/or diabetes.
2. Subjects with familial hypercholesterolemia.
3. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities.
4. Subjects with major surgical history relevant to the digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc.
5. Subjects with unusually high and/or low blood pressure and/or abnormal hematological data.
6. Subjects with severe anemia.
7. Pre- or post-menopausal women complaining of obvious physical changes.
8. Subjects who experienced unpleasant feeling during drawing blood in the past.
9. Subjects who are at risk of having allergic reactions to drugs or foods especially based on coffee, milk, egg, wheat, shrimp, soybean, chicken and/or pork.
10. Subjects with lactose intolerance.
11. Subjects who regularly take medicine, functional foods, and/or supplements which would affect lipid metabolism.
12. Subjects who regularly take medicine, functional foods, and/or supplements which would affect glucose metabolism.
13. Heavy smokers, alcohol addicts or subjects with disordered lifestyle.
14. Subjects who donated either 400 ml whole blood within 16 weeks (women), 12 weeks (men), 200 ml whole blood within 4 weeks (men and women), or blood components within 2 weeks (men and women), prior to the screening tests.
15. Pregnant or lactating women or women who expect to be pregnant during this study.
16. Subjects who currently participate in other clinical trials, or participate within the last 4 weeks prior to the study.
17. Any other medical and/or health reasons unfavorable to participation in the current study, as judged by the principal investigator.

Target sample size

24


Research contact person

Name of lead principal investigator

1st name Jun
Middle name
Last name NISHIHIRA

Organization

Hokkaido Information University

Division name

Department of Medical Management and Informatics

Zip code

069-8585

Address

59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan

TEL

011-385-4411

Email

nishihira@do-johodai.ac.jp


Public contact

Name of contact person

1st name Naoyuki
Middle name
Last name HONMA

Organization

Hokkaido Information University

Division name

Health Information Science Center

Zip code

069-8585

Address

59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan

TEL

011-385-4430

Homepage URL


Email

hisc-acad.res@s.do-johodai.ac.jp


Sponsor or person

Institute

Hokkaido Information University

Institute

Department

Personal name



Funding Source

Organization

Therabiopharma Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The ethics committee of Hokkaido Information University

Address

59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan

Tel

011-385-4411

Email

soumu@do-johodai.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

北海道情報大学 保健センター(北海道)


Other administrative information

Date of disclosure of the study information

2021 Year 07 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 05 Month 26 Day

Date of IRB

2021 Year 05 Month 26 Day

Anticipated trial start date

2021 Year 07 Month 27 Day

Last follow-up date

2021 Year 10 Month 26 Day

Date of closure to data entry

2021 Year 11 Month 09 Day

Date trial data considered complete

2021 Year 11 Month 16 Day

Date analysis concluded

2022 Year 03 Month 28 Day


Other

Other related information



Management information

Registered date

2021 Year 07 Month 01 Day

Last modified on

2022 Year 04 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051090


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name